Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,069
Employees1,069
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,069
Employees1,069

IONS Key Statistics

Market cap
10.06B
Market cap10.06B
Price-Earnings ratio
-34.11
Price-Earnings ratio-34.11
Dividend yield
—
Dividend yield—
Average volume
4.77M
Average volume4.77M
High today
$64.61
High today$64.61
Low today
$62.86
Low today$62.86
Open price
$63.85
Open price$63.85
Volume
1.41M
Volume1.41M
52 Week high
$64.72
52 Week high$64.72
52 Week low
$23.95
52 Week low$23.95

IONS News

TipRanks 1d
Arrowhead Pharmaceuticals Faces Patent Lawsuit from Ionis

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Seeking Alpha 2d
Arrowhead sues Ionis over patent dispute related to lead asset

Arrowhead Pharmaceuticals (NASDAQ:ARWR) sued Ionis Pharmaceuticals (NASDAQ:IONS) in a Delaware District Court on Wednesday as part of a patent dispute related t...

Arrowhead sues Ionis over patent dispute related to lead asset
Simply Wall St 2d
Why Ionis Pharmaceuticals Is Up 7.8% After FDA Breakthrough for ION582 and Positive Phase 3 Data

Ionis Pharmaceuticals recently announced that its experimental drugs achieved major milestones, including the FDA granting Breakthrough Therapy designation to I...

Why Ionis Pharmaceuticals Is Up 7.8% After FDA Breakthrough for ION582 and Positive Phase 3 Data

Analyst ratings

75%

of 28 ratings
Buy
75%
Hold
21.4%
Sell
3.6%

More IONS News

TipRanks 3d
Arrowhead files complaint for declaratory judgment against Ionis

Arrowhead (ARWR) announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against...

Benzinga 4d
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.’s IONS ION582 for Angelman syndro...

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
Simply Wall St 4d
Ionis Pharmaceuticals: Exploring Valuation as Shares Gain Momentum Without Major News

Advertisement Most Popular Narrative: 10.7% Undervalued If you have been following Ionis Pharmaceuticals (IONS), you may have noticed the stock has been attra...

Ionis Pharmaceuticals: Exploring Valuation as Shares Gain Momentum Without Major News
Seeking Alpha 4d
Ionis gets FDA breakthrough therapy status for angelman syndrome drug

Healthcare Ionis gets FDA breakthrough therapy status for angelman syndrome drug Sep. 09, 2025 11:18 AM ET Ionis Pharmaceuticals, Inc. (IONS) Stock By: Nilanjan...

Ionis gets FDA breakthrough therapy status for angelman syndrome drug

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.
CRISPR
Pfizer
AMD
Intel
Moderna
Taiwan Semiconductor Manu…
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.